Why billing designations matter before they ever reach a CTMS
Every line item on a clinical trial’s schedule of events has to be paid for by someone: the sponsor, a third-party payer such as Medicare, or the patient. That determination is not made inside a Clinical Trial Management System (CTMS) — it is made during Medicare Coverage Analysis (MCA), the billing-compliance review required before a trial activates under CMS National Coverage Determination (NCD) 310.1. The CTMS is where that finished determination gets recorded, applied to the actual visit calendar, and kept in sync as the protocol amends. OnCore, the CTMS platform built by Advarra (formerly Forte Research Systems), is one of the most widely deployed systems doing that job at academic medical centers and cancer centers, which is why “how do S, R, and Q actually get set in OnCore” is a real operational question for research billing offices, not just a coverage-analysis theory question.
This guide covers how the three-way billing-designation split — commonly labeled S, R, and Q — is derived from coverage analysis and then represented, procedure by procedure, inside a CTMS billing grid built on the OnCore model. It does not cover Medicare’s underlying coverage rules in detail; for the qualifying-trial test itself, see our Medicare Coverage Analysis guide.
The three designations: S, R, and Q
Institutional research billing offices commonly reduce every protocol procedure or visit-level item to one of three billing designations before it ever touches a CTMS calendar:
- S — Standard of Care. A service the patient would receive regardless of trial participation, because it is part of routine medical management for their condition. Standard-of-care items are billable to the patient’s insurance the same way they would be outside the trial, and their cost is not attributable to the research.
- R — Research (non-billable to insurance). A service performed only because the protocol requires it — extra scans, extra labs, study-specific procedures — with no standard-of-care justification. These are paid from the study budget (sponsor funds, grant funds, or institutional research accounts), never billed to Medicare or other third-party payers. Where a CTMS billing designation field has not yet been populated by coverage analysis, “R” is typically the conservative default, because billing an unreviewed item to insurance is the compliance failure institutions are trying to prevent.
- Q — Qualifying (routine cost of a qualifying clinical trial). An item that would ordinarily be research-only, but becomes billable to Medicare specifically because the trial itself has been determined to meet Medicare’s “qualifying clinical trial” (QCT) test under NCD 310.1 — testing an item or service within a Medicare benefit category, with therapeutic intent, and meeting one of the deeming criteria (for example, NIH funding or conduct under an FDA IND). Q-designated items are the “routine costs” NCD 310.1 requires Medicare to cover once trial-level qualification is established — distinct from S, which is billable independent of trial qualification at all.
The S/R/Q split maps directly onto how Medicare claims for qualifying trials are actually coded downstream: routine services in an approved research study carry HCPCS modifier Q1, the investigational item or service itself carries modifier Q0, and the institutional claim as a whole carries Condition Code 30 to flag it as trial-related. See our Condition Code 30 reference for how that claim-level flag and the Q0/Q1 line-item modifiers relate to each other. The coverage-analysis-to-CTMS billing designation is the upstream decision that determines which modifier, if any, a given claim line should ultimately carry.
How a CTMS like OnCore represents the designation
Publicly available institutional CTMS-support documentation (research computing and clinical research support offices that administer OnCore describe this consistently) shows the same basic structure:
- The study’s schedule of events (SOE) is built into OnCore as the protocol calendar — every visit and every procedure within a visit becomes a line item.
- Each line item carries a billing designation field. Documented OnCore behavior is that if coverage analysis has not yet been entered, every procedure defaults to a research designation until reviewed — the system does not assume standard-of-care or qualifying status on its own.
- The completed set of designations, together with the justification for each one, is compiled into what OnCore installations typically call a billing grid: a line-item table of study activities and visits, cross-referenced to billing designations, supporting designations, and (where an institution integrates a hospital charge master) the specific charge-master events and items each procedure maps to.
- The billing grid — not the protocol document itself — is what a research billing office, clinical research coordinator, and downstream claims-review process actually work from once the study is open to enrollment.
Exactly which screens, field labels, and menu paths an individual site sees varies by OnCore module configuration, institutional workflow, and version — Advarra does not publish a universal, publicly accessible field-by-field specification, and this guide does not claim more UI-level precision than institutional documentation supports. What is consistently documented across institutions is the structure above: SOE becomes a calendar, each calendar item gets a billing designation sourced from coverage analysis, and the compiled result is the billing grid that governs downstream billing.
Who sets the designation, and when
The designation itself is a coverage-analysis output, not a CTMS data-entry decision made independently by CTMS staff. In practice this means:
- Coverage analysis happens first, before study activation. A research billing analyst, coverage analyst, or research billing office — sometimes the same function that performs Medicare Coverage Analysis described in our MCA guide — reviews the protocol SOE against the study’s QCT status and each item’s standard-of-care justification, and produces the S/R/Q determination and a documented rationale for each line.
- The CTMS build translates that output into the calendar. Study coordinators or CTMS build staff enter the finished designations against each SOE line item as the protocol calendar is built in OnCore, rather than making independent billing judgments themselves.
- The principal investigator and/or study team typically reviews the resulting billing grid before activation, since the PI is often required to attest that the calendar reflects the protocol accurately.
- Designations are revisited on protocol amendment. Any amendment that adds, removes, or changes visits or procedures requires the billing grid to be reconciled against the updated SOE — an out-of-date billing grid relative to an amended protocol is one of the more common sources of billing-compliance risk institutions flag internally.
Why the designation matters downstream
The S/R/Q value entered against a CTMS line item is not administrative housekeeping — it is what ultimately determines which party’s claim (or budget line) that service should draw from:
- S-designated items flow to the patient’s normal insurance billing, exactly as they would outside the study.
- R-designated items are billed to the study budget (sponsor invoice or grant account) and should never appear on a claim submitted to Medicare or another third-party payer.
- Q-designated items are billed to Medicare (or the applicable payer) using the QCT billing pathway — carrying the Q0/Q1 HCPCS modifiers at the line-item level and Condition Code 30 at the claim level, as described in our Condition Code 30 term.
Many institutions run a reconciliation step between the CTMS billing grid and the hospital or physician billing system (commonly the electronic health record’s charge-capture module) specifically to catch mismatches — a research-only procedure billed to insurance, or a standard-of-care item mistakenly billed to the study — before a claim goes out. Getting this reconciliation wrong is precisely the exposure our False Claims Act liability in clinical trial billing guide covers: a research item billed to Medicare as though it were standard of care, or a qualifying trial’s routine costs never billed at all, are both compliance failures that trace back to a billing designation set incorrectly, or never reconciled, at the CTMS level.
Common failure points
- Coverage analysis completed, but never entered into the CTMS calendar — the grid still reflects the default (research) designation for items that were actually determined to be standard-of-care or qualifying, leaving the study budget covering costs it shouldn’t.
- Protocol amendments outpacing the billing grid — new or changed visits enter the calendar before coverage analysis has re-reviewed them, so new procedures inherit no reviewed designation at all.
- Designation set once and never reconciled against actual billing. The CTMS grid is a plan; claims and charge capture are what actually happened. Without a periodic reconciliation step, drift between the two accumulates silently.
- Treating “Q” and “S” as interchangeable. Both are ultimately billable to insurance, but they answer different questions — S is billable regardless of trial participation; Q is billable only because the trial itself qualifies under NCD 310.1. Conflating the two can misstate why a cost is covered, which matters if the qualifying-trial determination is ever challenged on audit.
Frequently asked questions
Is “S/R/Q” an OnCore-specific term, or a general coverage-analysis convention?
It is a coverage-analysis convention that institutions then configure into whatever CTMS they use. OnCore’s own documented behavior (research-designation default, procedure/visit-level billing designation fields, and a compiled billing grid) is consistent with the S/R/Q structure, but the letters themselves reflect how research billing offices classify Medicare coverage, not a label unique to one vendor’s software.
Does OnCore determine whether a trial qualifies under NCD 310.1?
No. Qualifying clinical trial status is a coverage-analysis determination made against CMS’s criteria — Medicare benefit category, therapeutic intent, and a deeming criterion such as NIH funding or conduct under an FDA IND — before the study is ever built in the CTMS. The CTMS records and applies that determination; it does not make it.
What happens if a billing designation is wrong when a claim is submitted?
An incorrect designation can result in a study budget absorbing a cost that should have been billed to Medicare, or — the more serious direction — a research-only item billed to Medicare or a sponsor that should not have been billed at all, which is the fact pattern underlying most clinical-trial-billing False Claims Act exposure. See our False Claims Act clinical trial billing guide for how that risk is typically identified and remediated.
Where does the billing grid come from if not directly from the protocol?
From the protocol’s schedule of events, but only after coverage analysis has assigned a billing designation and documented rationale to every line item — the billing grid is the coverage-analysis output represented at the calendar level, not a restatement of the protocol itself.
